Zynerba Pharmaceuticals, Inc. (ZYNE): Price and Financial Metrics


Zynerba Pharmaceuticals, Inc. (ZYNE)

Today's Latest Price: $5.48 USD

0.15 (-2.66%)

Updated Jun 3 10:42am

Add ZYNE to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ZYNE Stock Summary

  • Zynerba Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7.07% of US listed stocks.
  • With a price/sales ratio of 1,661.62, Zynerba Pharmaceuticals Inc has a higher such ratio than 99.79% of stocks in our set.
  • The volatility of Zynerba Pharmaceuticals Inc's share price is greater than that of 93.47% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Zynerba Pharmaceuticals Inc, a group of peers worth examining would be BPMX, RVNC, ADVM, PSTI, and PRTA.
  • Visit ZYNE's SEC page to see the company's official filings. To visit the company's web site, go to www.zynerba.com.
ZYNE Daily Price Range
ZYNE 52-Week Price Range

ZYNE Stock Price Chart More Charts


ZYNE Price/Volume Stats

Current price $5.48 52-week high $15.70
Prev. close $5.63 52-week low $2.55
Day low $5.40 Volume 309,444
Day high $5.67 Avg. volume 732,122
50-day MA $4.28 Dividend yield N/A
200-day MA $6.14 Market Cap 136.73M

Zynerba Pharmaceuticals, Inc. (ZYNE) Company Bio


Zynerba Pharmaceuticals is a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company was founded in 2007 and is based in Devon, Pennsylvania.


ZYNE Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ZYNE Latest Social Stream


Loading social stream, please wait...

View Full ZYNE Social Stream

Latest ZYNE News From Around the Web

Below are the latest news stories about Zynerba Pharmaceuticals Inc that investors may wish to consider to help them evaluate ZYNE as an investment opportunity.

Implied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options

Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

Zacks Investment Research | May 28, 2020

Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder

Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced positive top line results from the exploratory, open label Phase 2 BRIGHT (An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Autism Spectrum Disorder) trial. The trial was designed to assess the safety, tolerability and efficacy of Zygel™ in pediatric and adolescent patients with autism spectrum disorder (ASD). Zygel was administered to patients with moderate-to-severe symptoms of ASD as add-on therapy to their standard of care utilizing a variety of efficacy assessments.

Yahoo | May 27, 2020

Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

- Robust Response Sustained through Two Years of Treatment with Zygel™ in Patients from Phase 2 FAB-C Trial - - Top Line Results of Pivotal CONNECT-FX…

GlobeNewswire | May 26, 2020

Zynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters on the safety, efficacy and quality of life results of the Phase 2 BELIEVE (Open Label Study to Assess the Safety and Efficacy of Zygel™ (ZYN002) Administered as a Transdermal Gel to Children and Adolescents with Developmental and Epileptic Encephalopathy) clinical trial. The Virtual Session is online at http://www.aan.com/2020science.

Yahoo | May 26, 2020

Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year?

Is (ZYNE) Outperforming Other Medical Stocks This Year?

Yahoo | May 25, 2020

Read More 'ZYNE' Stories Here

ZYNE Price Returns

1-mo 46.92%
3-mo 33.66%
6-mo -2.66%
1-year -53.52%
3-year -71.44%
5-year N/A
YTD -9.27%
2019 103.37%
2018 -76.28%
2017 -19.69%
2016 54.82%
2015 N/A

Continue Researching ZYNE

Here are a few links from around the web to help you further your research on Zynerba Pharmaceuticals Inc's stock as an investment opportunity:

Zynerba Pharmaceuticals Inc (ZYNE) Stock Price | Nasdaq
Zynerba Pharmaceuticals Inc (ZYNE) Stock Quote, History and News - Yahoo Finance
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.9518 seconds.